# Final QA — Q0492–Q0531

Date: 2026-08-14
Scope: V2-Q0492 through V2-Q0531 (40 standalone NCLEX-RN items)
Reviewer: OpenAI clinical/source audit

## Final QA result

Clinical/source review: PASS WITH GOVERNANCE LIMITATIONS
Commercial release gate: CLOSED

All 40 items were re-reviewed for keyed-answer correctness, clinical plausibility, rationale consistency, source relevance, and overbroad/absolute wording. The batch remains intentionally outside the commercial release gate because the current master schema and override package do not yet prove every governance element required by the project-level final gate.

## Final-source corrections made during this pass

- V2-Q0506: replaced generic ONS homepage with the specific ONS Extravasation Management resource and section-level locator.
- V2-Q0507: replaced generic DailyMed homepage with a current 2026 albuterol label and section-level adverse-effect locator.
- V2-Q0522: replaced generic NCBI Bookshelf homepage with Nursing Management and Professional Concepts, Chapter 4, Table 4.2b.
- V2-Q0524: replaced generic NCBI Bookshelf homepage with Health Alterations, Chapter 12.5 Transition to Practice.
- V2-Q0529: replaced generic GOLD homepage with the 2026 GOLD Report and Pocket Guide landing page and report-level locator.

These corrections are versioned in `data/clinical_overrides_wave25i_final_source_fixes.json`.

## Independent currentness checks

Current or authoritative sources were independently rechecked for high-risk/currentness-sensitive claims including occupational HCV exposure, antineoplastic extravasation, albuterol adverse effects, servant leadership/preceptorship definitions, GOLD 2026 chronic bronchitis terminology, and peripheral artery disease claudication.

## Criteria reviewed

- Keyed answer clinical correctness: reviewed for all 40.
- Stem ambiguity / overbreadth: reviewed; material overstatements previously identified were corrected in Wave 25E–25I.
- Distractor clinical plausibility: reviewed at item level; no distractor was accepted as a second defensible best answer in this final pass.
- Rationale-to-key consistency: reviewed for all 40.
- Source relevance/currentness: reviewed; weak generic locators identified in the final pass were tightened where listed above.
- Blueprint category: inherited from the original V2 source rows and mapped by the master builder to the 2026 NCLEX client-need blueprint.
- Structural database integrity: enforced by the master build workflow.

## Governance limitations that remain before a project-level 10/10 commercial final gate

1. The current `questions` table does not persist dedicated fields for exact page/paragraph/section locator, source publication/version date, auditor identity, independent-QA status, rejection reason, or each individual final-gate dimension. `source_detail`, `clinical_audit_log`, and `editorial_flags_json` carry part of this information but do not fully implement the requested governance model.
2. The project-level release rule also requires `option_length_qc` PASS for commercial-ready items. This batch's Wave 25E–25I records were clinically reviewed but were not all populated with the legacy quantitative option-length QC record, so they must not be represented as commercially released.
3. Full-bank source/licensing review and independent release QA remain incomplete; therefore `commercial_release_ready` must remain false and the hard gate must remain CLOSED.

## Final disposition

Q0492–Q0531 are accepted as source-verified clinical production candidates after final clinical/source QA. They are NOT represented as final commercial-release-ready items until the remaining governance/QC requirements above are implemented and passed.
